|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001418,
umls-concept:C0016360,
umls-concept:C0016976,
umls-concept:C0020402,
umls-concept:C0022277,
umls-concept:C0086960,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0332174,
umls-concept:C0442027,
umls-concept:C0444956,
umls-concept:C0553695,
umls-concept:C1096776,
umls-concept:C1274040,
umls-concept:C1518578,
umls-concept:C1710133,
umls-concept:C2721771
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1996-11-5
|
|
pubmed:abstractText |
To date there is no established chemotherapeutic treatment for patients with unresectable locally advanced and/or metastatic carcinomas of the exocrine pancreas or the gallbladder. A multicenter Phase II trial has been performed by the Southern Italy Oncology Group with the aim of evaluating the clinical effectiveness and tolerability of weekly 5-fluorouracil (5-FU) in modulation with intravenous (i.v.) high dose levofolinic acid and oral hydroxyurea.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1300-7
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8826954-Adenocarcinoma,
pubmed-meshheading:8826954-Administration, Oral,
pubmed-meshheading:8826954-Aged,
pubmed-meshheading:8826954-Antidotes,
pubmed-meshheading:8826954-Antimetabolites, Antineoplastic,
pubmed-meshheading:8826954-Antineoplastic Agents,
pubmed-meshheading:8826954-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8826954-Carcinoma,
pubmed-meshheading:8826954-Disease Progression,
pubmed-meshheading:8826954-Drug Administration Schedule,
pubmed-meshheading:8826954-Female,
pubmed-meshheading:8826954-Fluorouracil,
pubmed-meshheading:8826954-Gallbladder Neoplasms,
pubmed-meshheading:8826954-Humans,
pubmed-meshheading:8826954-Hydroxyurea,
pubmed-meshheading:8826954-Infusions, Intravenous,
pubmed-meshheading:8826954-Injections, Intravenous,
pubmed-meshheading:8826954-Italy,
pubmed-meshheading:8826954-Leucovorin,
pubmed-meshheading:8826954-Leukopenia,
pubmed-meshheading:8826954-Male,
pubmed-meshheading:8826954-Middle Aged,
pubmed-meshheading:8826954-Pancreatic Neoplasms,
pubmed-meshheading:8826954-Remission Induction,
pubmed-meshheading:8826954-Survival Rate
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
|
|
pubmed:affiliation |
Service of Chemotherapy, Policlinico, University of Palermo, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
